Nicola Boschetti
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Nicola Boschetti has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
Christoph Kempf
ZLB Behring AG, Wankdorfstr. 10, CH-3000 Bern 22, Switzerland
2 shared publicationsMartin Stucki
ZLB Behring AG, Wankdorfstr. 10, CH-3000 Bern 22, Switzerland
2 shared publicationsPeter J. Späth
ZLB Behring AG
1 shared publication
Latest Publications
- 3 April 2006
- Published by Elsevier in Biologicals
- Vol. 35 (1) , 35-42
Pathogen inactivation and removal procedures used in the production of intravenous immunoglobulins
- 3 April 2006
- Published by Elsevier in Biologicals
- Vol. 35 (1) , 35-42
Pathogen inactivation and removal procedures used in the production of intravenous immunoglobulins
- 1 December 2005
- Published by Springer Nature in Clinical Reviews in Allergy & Immunology
- Vol. 29 (3) , 333-344
Virus safety of intravenous immunoglobulin
Patients with immunodeficiencies or some types of autoimmune diseases are dependent on safe therapy with intravenous immunoglobulins. State-of-the-art manufacturing processes provide a high safety standard by incorporating virus elimination procedures into the manufacturing process. Based on their mechanism, these procedures are grouped into three classes: partitioning, inactivation, and removal based on size. Because of current socioeconomic and ecological changes, emerging pathogens continue to be expected. Such pathogens may spread very quickly because of increased intercontinental traffic. Severe acute respiratory syndrome-coronavirus and the West Nile virus are recent examples. Currently, it is not possible to predict the impact such a pathogen will have on blood safety because the capacity for a globally coordinated reaction to such a threat is also evolving. The worst-case scenario would be the emergence of a transmissible, small, nonenveloped virus in the blood donor population. Examples of small nonenveloped viruses, which change host and tissue tropism, are discussed, with focus on parvoviridae. Although today’s immunoglobulins are safer than ever, in preparation for future challenges it is a high priority for the plasma industry to proactively investigate such viruses on a molecular and cellular level to identify their vulnerabilities.
- 1 December 2005
- Published by Springer Nature in Clinical Reviews in Allergy & Immunology
- Vol. 29 (3) , 333-344
Virus safety of intravenous immunoglobulin
Patients with immunodeficiencies or some types of autoimmune diseases are dependent on safe therapy with intravenous immunoglobulins. State-of-the-art manufacturing processes provide a high safety standard by incorporating virus elimination procedures into the manufacturing process. Based on their mechanism, these procedures are grouped into three classes: partitioning, inactivation, and removal based on size. Because of current socioeconomic and ecological changes, emerging pathogens continue to be expected. Such pathogens may spread very quickly because of increased intercontinental traffic. Severe acute respiratory syndrome-coronavirus and the West Nile virus are recent examples. Currently, it is not possible to predict the impact such a pathogen will have on blood safety because the capacity for a globally coordinated reaction to such a threat is also evolving. The worst-case scenario would be the emergence of a transmissible, small, nonenveloped virus in the blood donor population. Examples of small nonenveloped viruses, which change host and tissue tropism, are discussed, with focus on parvoviridae. Although today’s immunoglobulins are safer than ever, in preparation for future challenges it is a high priority for the plasma industry to proactively investigate such viruses on a molecular and cellular level to identify their vulnerabilities.